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E-mail address: a.impagliazzo@lumc.nl (A. ImpaglOculopharyngeal muscular dystrophy is caused by small alanine expansions in polyadenylate bind-
ing protein nuclear 1 (PABPN1) protein resulting in its intranuclear accumulation in skeletal muscle.
3F5 llama antibody speciﬁcally interferes with the PABPN1 aggregation process in vitro and in vivo.
To understand the structural basis for its epitope recognition we mapped the binding interface of
3F5 with PABPN1 and provide a structural model of the 3F5-PABPN1 complex. We show that 3F5
complementarity determining regions create a cavity in which PABPN1 a-helix domain resides by
involving critical residues previously implicated in the aggregation process. These results may
increase our understanding of the PABPN1 aggregation mechanism and the therapeutic potential
of 3F5.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Antibody technology has recently found many therapeutic
applications [1]. Heavy chain antibodies from camelids (HCAb)
[2] have further boosted the ﬁeld. These antibodies, which are de-
void of light chains, have a conserved framework whereas signiﬁ-
cant conformational differences occur in the complementarity
determining regions (CDRs), which create speciﬁcity and afﬁnity
for antigen recognition.
These antibodies are useful for biological applications because
of their high epitope afﬁnity, high expression level, stability and
solubility and, are also advantageous for therapeutic applications
due to their small size and low immunogenicity [2].
In our previous study the llama antibody fragment 3F5 recog-
nizing the poly (A)-binding protein nuclear 1 (PABPN1) was se-
lected from a non-immune HCAb library [3]. A genetic lesion in
the coding region of the PABPN1 gene is the cause of oculopharyn-
geal muscular dystrophy (OPMD). OPMD is an autosomal dominant
disease that, like e.g. Huntington’s disease, belongs to a group ofchemical Societies. Published by E
protein nuclear 1; OPMD,
ain antibody from camelids;
chroism; PABPN1L, PABPN1
iazzo).disorders, which is associated with the accumulation of misfolded
protein [4]. A characteristic feature of OPMD is therefore the pres-
ence of ﬁlamentous intranuclear inclusions in skeletal muscle ﬁ-
bers [5].
PABPN1 is a multi-domain protein of 306 amino acid residues
(32.8 kDa); its function is mainly to provide a scaffold for the bind-
ing of factors that mediate mRNA polyadenylation [6].
The human PABPN1 gene contains a (GCG)6(GCA)3GCG repeat
coding for a polyalanine stretch of 10 alanines at the protein N-ter-
minus. In OPMD patients the (GCG)6 moiety is expanded to (GCG)8–13,
generating instead of 10 alanines an array of 12–17 alanines [4].
This multi-domain protein also contains a glutamate rich N-termi-
nal domain essential for the stimulation of the poly(A)polymerase,
an a-helix domain of30 amino acid residues (Leu119-Gln147), an
RNA binding domain and an arginine rich C-terminal domain [6].
The PABPN1 epitope for 3F5 was mapped via western blotting
and is located between amino acids 113 and 133 in the a-helix do-
main of the protein [3]. Transient transfection experiments showed
that 3F5 can prevent PABPN1 aggregation in different cells lines
overexpressing mutant PABPN1. These results highlight the poten-
tial of 3F5 to prevent or cure OPMD, which is further corroborated
by the observation of disease rescue in a Drosophila model for
OPMD in the presence of 3F5 [7]. For this reason it seemed impor-
tant to determine the molecular basis of the interaction of 3F5 with
PABPN1.lsevier B.V. All rights reserved.
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suited to study protein–protein interactions at the single amino
acid level. In the present study we therefore applied NMR spectros-
copy to localize the interaction area of 3F5 with its antigen. We
characterized the kinetics of the binding and we calculated a model
structure of the complex that may provide useful insight into 3F5’s
disaggregating propensity.
2. Materials and methods
2.1. NMR
For expression and puriﬁcation of labeled 3F5 see Supplemen-
tary data 1.1. For the assignment of the 1H-15N HSQC spectrum
the NMR sample of free 3F5 contained 1.6 mM 15N-13C 3F5 in
20 mM potassium phosphate buffer at pH 6.5, 1 M urea, 10% D2O
and 150 mM NaCl. The bound form sample contained 2.4 mM of
PABPN1 peptide corresponding to a stoichiometric excess of 1:1.5.
For the titration experiment the NMR sample (0.5 ml) contained
0.1 mM 15N-3F5 in the same buffer. The sample containing the free
protein was heated at 80 C for 5 min before each experiment in
order to improve the HSQC spectra.
A stock solution of PABPN1 peptide (Ala113-Lys145) was pre-
pared by dissolving the peptide into the same buffer to achieve a
concentration of 5.13 mM.
For the assignment experiments, the data set included for the
free form of 3F5 and the bound one, the following spectra:
2D-15N-1H-HSQC, 3D-HNCACB, 3D-HNCA, 3D-HNCO and 3D-HNC-
ACO. All NMR spectra were recorded at 30 C on a Bruker DMX
600 MHz with TCT Cryo-probe. For the titration experiments an
NMR sample containing 15N-3F5 was titrated with microliter ali-
quots of the PABPN1 peptide from the stock solution to give a mo-
lar ratio of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2, 1.5 and 2.0.
All spectra were processed in AZARA (http://www.bio.cam.a-
c.uk/azara) and analyzed with the assignment software ANSIG [8].
The average chemical shift perturbation [9] was calculated by
using the equation below:
Ddavg ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDdN=5Þ2 þ DdH2
2
s
ð1Þ
In which DdN and DdH represent the change in the chemical
shifts of the amide nitrogen and proton of a given residue, between
the free and bound forms.
2.2. Fluorescence and stopped-ﬂow
Fluorescence measurements were taken on a Cary Eclipse Spec-
trophotometer. All measurements were performed at 22 C using
2 mM potassium phosphate buffer at pH 6.5 containing and
150 mM NaCl.
Stopped-ﬂow experiments were performed using a computer-
controlled Applied-Photophysics SX18MV system equipped with
a PBP 05-109 Spectra kinetic monochromator. The time depen-
dence of the binding process was recorded using at least 10 differ-
ent concentrations in the range of the dissociation constant for the
ligand. The samples were prepared from stock solutions containing
20 lM 3F5 and 5.13 mM of PABPN1 peptide, respectively.
The ﬁrst experiment was performed using pseudo ﬁrst-order
conditions, obtained by keeping constant the protein concentration
in syringe A at 50 nM and varying the unlabeled peptide concen-
tration in syringe B [PAPBN1] from 0.5 to 5 lM. The second exper-
iment, with the HiLyte 647 labeled peptide, was performed by
keeping PABPN1 labeled peptide concentration constant in syringe
A (1 lM peptide-HiLyte 647), while the protein concentration was
varied in syringe B from 0.5 to 8 lM 3F5.2.3. Docking calculations
Docking calculations were carried out with the software BIG-
GER (Bimolecular complex calculations with global evaluation
and Ranking) [10] which require as input a 3D structure for each
of the two interacting proteins (target and probe). The simulation
was carried out without experimental restraints.
The 3D structure of 3F5 was obtained using homology modeling
of Swiss-Model server. As a model the structure of the camelized
human antibody fragment HCAb (PDB 1G9E) was used. 3F5 shares
71% sequence similarity with this HCAb. The peptide model was
obtained using Phyre version 2.0 (http://www.sbg.bio.ic.ac.uk/
phyre).3. Results
3.1. 3F5 and PABPN1 peptide complex
To determine the binding interface of 3F5 we aimed to assign its
1H-15N-HSQC spectra. Initially the spectra presented a very poor
dispersion indicating not only that 3F5 was dimerizing but also
that it was partially unfolded (Supplementary data Fig. S1). By per-
forming size exclusion chromatography, the dimer and the mono-
mer could be separated. The monomer yielded a better spectrum
(Supplementary data Fig. S3) which was further improved by add-
ing urea up to 1 M and heating the NMR sample at 80 C. This
behavior has been observed before for HCAb’s [11]. Backbone
1H,15N and 13C chemical shift (with exception for the side chains)
were obtained from the sequential assignment set of 3D NMR spec-
tra. For 3F5 in the free form it was possible to assign the majority of
the framework residues while for many of the CDR residues spin
systems were often incomplete, making impossible their sequen-
tial assignment (chemical shift assignments are deposited at
BioMagResBank BMRB ID: 16586 for 3F5 in the free form and ID:
7434 for 3F5 in the bound form with PABPN1 peptide).
Because of technical limitations due to the precipitation prone-
ness of recombinant full length PABPN1 and size limitations of
NMR, in our mapping studies we used a peptide previously shown
to represent the a-helix domain of PABPN1 [6]. The a-helix sec-
ondary structure of the peptide was conﬁrmed by circular dichro-
ism (Supplementary data Fig. S9).
To determine the binding area between 3F5 and the PABPN1
peptide, the latter was titrated into 3F5. Chemical shifts are very
sensitive to variations in the local electronic environment, and
thus, changes in 1HN and 15N shifts upon titration can be used to
map the binding interface. Microliter aliquots of the peptide corre-
sponding to molar ratios from 0.1 to 2.0 were added to 3F5 and
15N-1H-HSQC spectra were recorded at each point.
Upon peptide addition, some 3F5 resonances disappeared due
to a diminished presence of the free form, and, at the same time,
new peaks arose which correspond to 3F5 bound to the PABPN1
peptide (Fig. 1a and b). The intensities of the new peaks increased
with addition of the peptide (Supplementary data Fig. S7a). Peaks
that were present in the same position both in the free and the
bound form showed no change in intensities (Supplementary data
Fig. S7b). It should be noticed that a possible presence of antigen-
induced dimer formation of 3F5 would result in undetectable NMR
signals since the dimer HSQC spectra only show few amide side
chains peaks (Supplementary data 1.2). On the contrary, by adding
the PABPN1 peptide to 3F5 the number of peaks increases, indicat-
ing that no dimerization was occurring. To support the evidence
obtained via NMR on complex formation between monomeric
3F5 and the PABPN1 peptide additional afﬁnity chromatography
experiments were performed (Supplementary data Figs. S5 and
S6). Monomeric 3F5 was loaded with the Hylite 647 labeled
Fig. 1. [15N-1H]HSQC spectra of 3F5 in the free form (a) and in the bound form (b), in the presence of 120% PABPN1 peptide.
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vis detection absorbances were independently recorded at
280 nm for 3F5 and at 647 nm for the PABPN1 peptide, respec-
tively. The 3F5-PABPN1 peptide complex eluted in a single peak,
demonstrating unequivocally that a complex between 3F5 and
the PABPN1 peptide was formed.
From these observations and taking into account that all spectra
were recorded while maintaining temperature, pH and salt con-
centration constant, we conclude that the observed changes are a
consequence of the binding.
Another pronounced effect of substrate addition was the gener-
ally improved peak dispersion and a more homogeneous intensity
of the peaks (Fig. 1b) indicating a better-structured protein com-
pared to the free form. The presence of new peaks in the spectra
of the bound form indicates an interaction between the 3F5 and
the PABPN1 peptide in the slow exchange regime on the NMR time
scale, consistent with tight binding.Fig. 2. 3F5 model structure surface representation using the following color code: res
resonances that exhibit a chemical shift change between the free and the bound form a
proline residues and in light yellow residues with resonances that could not be assigne
sequence.To deﬁne the binding area on the 3F5 surface it was necessary to
assign also the spectra of the bound state. The same 3D spectra re-
corded for the assignment of the free 3F5 were acquired for 3F5
bound to the PABPN1 peptide. The better dispersion of the reso-
nances in the bound form allowed complete backbone assignment
with the exception, due to signal overlap, of residue Gly35, Cys98
and Arg110 (Supplementary data Fig. S8).
Mapping on the 3F5 3D structure model the resonances appear-
ing during the titration and the residue resonances most affected in
their chemical shift upon binding, allowed us to deﬁne the binding
area (Fig. 2).
In Fig. 3 the changes in the average chemical shift (Ddavg) of
3F5 upon complex formation with the PABPN1 peptide are shown
in a bar chart. Ddavg was determined only for 3F5 residues as-
signed both in the free and in the bound form. For clarity of the
picture Ddavg has been assigned as 1 for those residues that could
only be assigned in the bound form but not in the free form dueidues with assigned resonances only in the bound form are in red, residues with
re orange. In grey are depicted the residues not affected upon binding, in black are
d. On the left is depicted the model structure of PABPN1 peptide with its residues
Fig. 3. Bar chart of the changes in the average chemical shift (Ddavg) of 3F5 upon complex formation with PABPN1 peptide.
Fig. 4. Representative stopped-ﬂow ﬂuorescence traces recorded by monitoring the
Trp emission of 50 nM 3F5 after the addition of 0.5 lM (black), 1 lM (light grey)
and 4 lM (dark grey) PAPBN1 peptide (kex = 280 nm, kem > 335nm). Solid lines are
mono-exponential ﬁts to the data, providing the rate constants plotted against
[PAPBN1] in the inset. A linear ﬁt to the data yielded kon = 21 ± 2 lM1 s1 and
koff = 17 ± 5 s1 (Scheme 1). The residuals of the ﬁt obtained for the data with
[PAPBN1] = 1 lM are shown in the upper panel.
Scheme 1.
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The most affected residues are all located in the CDR regions
(CDR1: Phe31, Ser32, Gly33, Tyr34, Gly35, Met36, CDR2: Ala51,
Ala52, Ile53, Ser54, Trp55, Arg56, Gly57, Gly58, Asn59, Thr60,
Tyr61 and Tyr62, CDR3: Ser99, Gly100, Phe101, Val102, Arg103,
Thr104, Arg105, Asp106, Pro108, Ser109, Arg110, Ile111, Arg112,
Asn113 and Tyr114). Some more internally located residues also
presented chemical shift perturbations (Gly37, Trp38, Phe39),
probably due to an indirect rigidity effect caused by the ligand.
Residue Arg74, although not in the CDR, is exposed on the surface
and very close to the binding area as are residues Asn79, Thr80
and Val81.
3.2. Fluorescence
In order to characterize the complex formation between 3F5
and the PABPN1 peptide kinetically and thermodynamically, a
ﬂuorescence study was performed. The 3F5 protein contains four
endogenous tryptophan residues: Trp38 located nearby CDR1,
Trp55 in the middle of CDR2, Trp80 in the middle of the b-sheet
and Trp113 at the end of CDR3. The NMR signals of Trp55 and
Trp115 were strongly perturbed in the experiments described
above, suggesting that they are involved in PABPN1 binding.
Since the near-UV tryptophan ﬂuorescence is a sensitive repor-
ter of the local microenvironment of the residue, we assessed
whether we could use the Trp ﬂuorescence to study the binding
process. The peptide does not contain ﬂuorescent residues and,
thus, does not contribute to the observed emission. Prolonged
experiments making use of the 3F5 tryptophan ﬂuorescence were
hindered by the slow precipitation of the protein, causing light-
scattering in the solution and a gradual decrease in the 3F5 trypto-
phan emission, therefore obscuring possible emission changes due
to the complex formation. This effect was circumvented by
employing stopped-ﬂow ﬂuorescence kinetics to study the binding
under pseudo ﬁrst-order conditions ([3F5] = 50 nM, [PABPN1] be-
tween 0.5 and 5 lM, kex = 280 nm, kem > 320 nm). Upon rapid mix-
ing of 3F5 and the peptide, a small but reproducible increase in
tryptophan emission was observed to 1.04 of the original value,
after which the emission remained stable for several seconds
(Fig. 4). The obtained kinetic traces could be ﬁtted to a mono-expo-
nential function at all [PABPN1] employed, yielding the rate
constants, kobs, plotted in the inset of Fig. 4. The apparent linear in-
crease in kobs with [PABPN1] is consistent with a simple two-state
binding model (Scheme 1).
A linear ﬁt to the data yielded kon = 21 ± 2 lM1 s1,
koff = 17 ± 5 s1 and, thus, Kd = 0.8 ± 0.3 lM (=koff/kon). Note thatthe peptide concentration was determined by weight, introducing
a relative large error in the obtained parameters.
To investigate the binding kinetics further and to corroborate
that the small change in 3F5 tryptophan ﬂuorescence is associated
with PAPBN1 binding, we employed PABPN1 peptide quantita-
tively labeled with the red-emitting label HiLytePlus™ 647 at the
N-terminus (PABPN1L).
The endogenous 3F5 tryptophan emission was used to excite
the HiLytePlus™ 647 label through a FRET mechanism. Even
though the dye absorbance around 340 nm is small with respect
to the absorbance maximum at 647 nm, it still sufﬁces for energy
transfer from tryptophan to the dye, provided that the distance
between tryptophan and the label is within (or slightly larger
Fig. 6. Normalized stopped-ﬂow ﬂuorescence traces of 1 lM HiLytePlus™ 647
labeled PABPN1 peptide mixed with increasing [3F5] as indicated in the graph. The
sample was excited at 280 nm and all label ﬂuorescence above 645 nm was
collected. The solid lines represent a simulation of the data using Scheme 1. The
time axis on the right side of the break shows the slow increase in HiLytePlus™ 647
ﬂuorescence on a longer timescale. The residuals of the ﬁt obtained for the data
with [3F5] = 1 lM (short time scale) and [3F5] = 8 lM (long time scale) are shown
in the upper panel.
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tance, calculated using the label absorption and the tryptophan
emission spectra, amounts to 30 Å. This distance is in agreement
with the distance measured in the model structure of the com-
plex (see docking results). The occurrence of FRET between the
3F5 tryptophan and the label would be reported as a decrease
in 3F5 tryptophan ﬂuorescence and an increase in the label emis-
sion upon the binding of PABPN1L and upon excitation at
280 nm. This was observed indeed: whereas the 3F5 tryptophan
ﬂuorescence slightly increased upon the binding of the unlabeled
peptide, it decreased to approximately 0.75 of the original inten-
sity in a titration of 1 lM 3F5 with PABPN1L (Fig. 5). An increase
in label ﬂuorescence was seen concomitantly. Although we re-
frained from quantitatively interpreting the binding isotherms
due to the slow aggregation of 3F5 and an autoﬂuorescence con-
tribution to the label emission, the results clearly conﬁrm the
occurrence of Trp-to-dye FRET. Thus, at least one of the ﬂuoresc-
ing tryptophan residues occurs within Förster distance in the
3F5-PABPN1L.
The stopped-ﬂow experiments were repeated, but now moni-
toring the label ﬂuorescence of 1 lM PABPN1L being mixed with
various [3F5] between 0.5 and 8 lM, again using 280 nm excitation
(Fig. 6). Global ﬁtting of the traces recorded between 2 and
50 msec. reaction time using numerical simulation of Scheme 1
yielded kon = 68 lM1s1 and koff = 14 s1 with a calculated error
of ±10% for both values (Kd = 0.20 ± 0.04 lM). It should be noted
that the dissociation rate value is in agreement with the slow ex-
change mode showed in the NMR results. Following the PABPN1L
emission for a longer time (25 s) revealed a slow second phase
with a rate constant of 0.2 s1 that was independent of the 3F5
concentration (Fig. 6). This suggests a unimolecular reorganization
of the complex following the association of 3F5 and PABPN1
(Scheme 2).
The amplitude of this signal is 10-fold lower than the rapid in-
crease of PABPN1L emission in the ﬁrst binding phase. The phase is
not observed when the 3F5 tryptophan emission is utilized as the
reporter for the binding process.Fig. 5. Trp-to-dye FRET between the 3F5 Trp residues and the PABPN1L peptide
carrying the HiLytePlus™ 647 label at its N-terminus. A solution of 1 lM 3F5 was
titrated with PAPBN1L and emission spectra were recorded between 300 and
800 nm (kex = 280 nm), revealing a decrease in 3F5 Trp (blue) emission and an
increase in the emission of the label (red) with increasing [PAPBN1L]. The inset
shows the amplitude of the change in Trp (open squares) and label (black circles)
emission as a function of [PAPBN1L]. The decrease in Trp emission has been plotted
as an increase to facilitate comparison with the change in label emission.
Scheme 2.The results can be rationalized by assuming an increase in the
Trp-to-dye FRET efﬁciency due to a shortening of the distance (or
a change in orientation) between the donating Trp residues and
the ﬂuorescing label. This may be connected with a conformational
stabilization of the 3F5/PABPN1L complex or a slow process involv-
ing the label only. We note that the apparent Kd of 0.2 lM obtained
from the kinetic experiments reﬂects the dissociation constant of
the initial complex (3F5-PABPN1), while the Kd of the stabilized
complex (3F5-PABPN1*) may be much lower.
3.3. Docking results
Rigid body docking calculations were performed using the BiG-
GER software [10] with 3F5 as the target and the PABPN1 peptide
as the probe. A scoring function was used to select the best struc-
ture. This function combines several types of interactions: geomet-
ric packing of the surfaces, electrostatic interaction, desolvation
energy and pair-wise propensities of the amino acid side chains
across the molecular interface. Experimental information was not
used as restraints. In principle, it is possible to use the chemical
shift perturbations observed for 3F5 as an additional scoring term.
However, the NMR results show that the CDR loops become more
structured upon binding of the peptide, resulting in chemical shift
changes not only in the interface area, but also in the surroundings.
Consequently, the use of the chemical shift perturbations for scor-
ing is not reliable.
In the structure with the highest score (Fig. 7), out of the 5000
structures produced, part of the peptide (Lys135-Lys145) is not in
contact with 3F5, whereas the rest lies in the cavity formed by the
CDRs, on the right side of CDR3 and just below it. Part of the inter-
face is polar with some positive charges on 3F5 and negative ones
on the peptide, with the following interactions (from peptide to
3F5): Glu134-Arg105, Ala133-Thr104, Glu132-Thr104, Glu131-
Thr104, Glu130-Arg105, Met129-Trp55/Tyr34 and Glu128-Asn59.
The lower part of the interface comprises more hydrophobic inter-
actions with contacts between Val126-Phe101, Arg125-Asn59,
Ile122-Ala52, Ala121-Tyr62, Glu120-Tyr61, Leu119-Tyr61/Phe49
and Glu118-Phe39. In this model of the structure, the peptide sits
in the centre of the binding area as deﬁned by the NMR experi-
ments (Fig. 2) and the interactions are also in good agreement with
Fig. 7. Surface representation of the top ranking orientation of PABPN1 peptide (blue) on 3F5. 3F5 is depicted with the same color coding used in Fig. 2.
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3F5 to seven different PABPN1 mutants has been analyzed map-
ping the epitope between amino acids 113 and 133. Residues
Val126, Met129, Glu131 were shown to be essential for the binding
and these are all located in the interface of our docking model.
Point mutations of residues Lys135, Leu136 and Val143, which
were not affecting 3F5 binding are located outside the interface
in our model. Interestingly, changing the weight factor in favour
of either the polar or the hydrophobic interaction yields a top
structure that agrees less with both the NMR results and the epi-
tope studies.
4. Discussion
NMR spectroscopy, chromatography, stopped-ﬂow experiments
and docking calculations were performed, yielding a ﬁrst structural
model of the complex between the a-helix domain of PABPN1 and
the disaggregating antibody fragment 3F5.
NMR spectroscopy was used to investigate the interaction inter-
face between 3F5 and PABPN1. In 3F5’s free form many resonances
belonging to the CDR regions are lacking in the NMR spectra. This
poor degree of structure deﬁnition of the CDRs loops of a free HCAb
has been reported in previous studies [13]. 3F5, compared to other
HCABs of known structure [14], presents a longer CDR3 (six resi-
dues longer compare to e.g. H14, PDB 1G9E) and is not constrained
by an interloop disulphide bond that usually imposes conforma-
tional restraints on the loop ﬂexibility in the absence of the anti-
gen. These features may render 3F5 exceptionally unstructured in
absence of its epitope. Previously, it was shown that antigens can
induce structural changes on a thermically denatured HCAb [11].
In 3F5 such structural changes are detectable without the need
to denature the protein, which may be attributable to the dynamic
nature of all three CDRs in 3F5. Upon antigen addition, the CDR re-
gions of 3F5 are readily stabilized and adopt a well-deﬁned confor-
mation resulting in a signiﬁcant improvement of the spectra in
terms of intensities uniformity and peaks dispersion.
The most affected areas of the 3F5 surface upon PABPN1 bind-
ing are the three CDR regions and the N-terminal domain, which
are all located on the same side. The docking model suggests that
part of the a-helix domain ﬁts into the cavity and protruding loops
formed by the CDRs, a feature characteristic for the llama single
domain antibody. This model structure not only is in good agree-
ment with the NMR data but also with the epitope mapping exper-
iments that have been previously performed on the full lengthPABPN1 protein [3]. Taking into account the biophysical character-
istics of the binding area between 3F5 and PABPN1 we conclude
that the structural basis for such strong binding between 3F5 and
PABPN1 must not only rely on the presence of a large interaction
interface characteristic of the llama single domain antibody but
also on the fact that both 3F5 and the PABPN1 peptide can poten-
tially offer the same number of polar and hydrophobic residues to
form a new set of packing interactions able to stabilize the
complex.
Several studies highlighted the importance of the a-helix do-
main of PABPN1. The a-helix domain seems not only essential
for the function of PABPN1, but also for its aggregating propensity.
The a-helix domain is essential for the activity of poly(A)polymer-
ase [5,15] and deletion of two glutamate residues (Glu131 and
Glu132) from the a-helix domain of PABPN1, both of which were
shown to be involved in the binding with 3F5, results in an in-
creased proportion of soluble PABPN1 [16]. Similar results were
also obtained when deletion of the entire a-helix domain or substi-
tution of Leu136 prevented formation of insoluble PABPN1 depos-
its [5]. In Drosophila, ﬂies co-expressing mutant PABPN1 and 3F5
showed reduced aggregate sizes and dispersed inclusion formation
compared to ﬂies only expressing mutant PABPN1 [7]. Further-
more, in ﬂies expressing mutant PABPN1 with the entire a-helix
deleted, 3F5 could not interfere with the aggregation process and
thus not rescue the disease phenotype. This result clearly shows
that the curative effect of this antibody depends on its ability to
bind to the a-helix domain of full length PABPN1 in vivo.
As for many protein-aggregation disorders [17], although the
aggregate for a long time has been considered the cause of cellular
dysfunction, recent studies suggest that early oligomeric structures
might represent the most toxic species [7,17,18]. Although the
relationship between the alanine expansion and the disease mech-
anism in OPMD is currently not well understood [19], 3F5 by bind-
ing to a functionally important domain that is not directly affected
by the genetic lesion, may serve an important tool to address the
question how the alanine expansion changes the conformation of
PABPN1 in relation to its normal function, toxicity and aggregation.
Altogether, these studies suggest a crucial role of the a-helix
domain in the aggregation process of PABPN1. Based on previous
studies and the present results we propose that 3F5 interferes with
this aggregation process by binding to the a-helix domain via
hydrophobic and polar interactions. Although this model needs
further conﬁrmation, the identiﬁcation of critical binding residues,
the mechanism of binding and the nature of the binding interface
1564 A. Impagliazzo et al. / FEBS Letters 584 (2010) 1558–1564could help to understand the complex aggregation mechanism of
PABPN1 and its correlation to the disease as well as guide studies
to increase the therapeutic potential of 3F5.
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